Miscellaneous

Miscellaneous
Pressrelease: The market for CNS drugs across the 7MM was worth a substantial $95.5 billion in 2007 www.companiesandmarkets.com adds new report - Commercial Insight - CNS Market Overview - Commercial dynamics and outlook of the neurology, pain and psychiatry market sectors http://www.companiesandmarkets.com/Summary-Market-Report/Commercial-Insight-CNS-Market-Overview-Commercial-dynamics-and-outlook-of-the-neurology,-pain-and-psychiatry-market-sectors-30341.asp Introduction The market for CNS drugs across the 7MM was worth a substantial $95.5 billion, accounting for a 21.4% share of the total pharmaceutical market value in 2007. Despite stalling R&D productivity and the genericization of the [more] Pressrelease: The continued uptake of existing brands and the launch of two opioid antagonists will cause the market to grow at a compound annual growth rate of 13.5% from 2006 to reach $304m www.companiesandmarkets.com adds new report - Pipeline Insight - Substance Dependence - Part II - Alcohol http://www.companiesandmarkets.com/Summary-Market-Report/Pipeline-Insight-Substance-Dependence-Part-II-Alcohol-30340.asp Introduction The continued uptake of existing brands and the launch of two opioid antagonists will cause the market to grow at a compound annual growth rate of 13.5% from 2006 to reach $304m across the seven major markets by 2016. The alcohol dependence market requires a [more] Pressrelease: The ALS market was worth $148m in 2006 across the seven major markets www.companiesandmarkets.com adds new report - Pipeline Insight - Orphan Diseases in CNS - Part II - Amyotrophic Lateral Sclerosis http://www.companiesandmarkets.com/Summary-Market-Report/Pipeline-Insight-Orphan-Diseases-in-CNS-Part-II-Amyotrophic-Lateral-Sclerosis-30339.asp Introduction The ALS market was worth $148m in 2006 across the seven major markets. With the only approved treatment for ALS, Sanofi-Aventis's Rilutek (riluzole), facing generic incursion in 201213, future growth in this market is dependent on the success of pipeline drugs. Scope Scenario [more] Pressrelease: Deep Brain Stimulation is by far the most common surgical procedure used in the 7MM and neurologists indicated that over 70% of patients receiving it experience both a reduction in PD symptoms and a reduction in the dose of pharmacological medication. www.companiesandmarkets.com adds new report - Stakeholder Insight - Parkinson's Disease - Evidence of neuroprotection essential to progress treatment dynamics http://www.companiesandmarkets.com/Summary-Market-Report/Stakeholder-Insight-Parkinsons-Disease-Evidence-of-neuroprotection-essential-to-progress-treatment-dynamics-30338.asp Introduction Parkinson's disease (PD) is a progressive, degenerative condition of the central nervous system that affects the way the brain coordinates body movements, including walking, talking and writing. PD affects less than 1% of the population in the seven major markets (7MM); [more] Pressrelease: The delayed launch of antipsychotic bifeprunox will impact Solvay's commercial performance over 2006-12 www.companiesandmarkets.com adds new report - Solvay S.A - PharmaVitae Profile http://www.companiesandmarkets.com/Summary-General/Solvay-S.A-PharmaVitae-Profile-30337.asp Introduction This analysis examines the historical and forecast performance for Solvayin the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information. Reasons [more] Pressrelease: Servier’s outlook will be shaped primarily by the launch of generic copies of its largest product, Coversyl, in 2007 www.companiesandmarkets.com adds new report - Les Laboratoires Servier - PharmaVitae Profile http://www.companiesandmarkets.com/Summary-General/Les-Laboratoires-Servier-PharmaVitae-Profile-30336.asp Introduction This analysis examines the historical and forecast performance for Servier in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and [more] Pressrelease: Asthma and COPD therapy Spiriva will act as the key driver of Boehringer Ingelheim's commercial performance out to 2012 www.companiesandmarkets.com adds new report - Boehringer Ingelheim GmbH - PharmaVitae Profile http://www.companiesandmarkets.com/Summary-General/Boehringer-Ingelheim-GmbH-PharmaVitae-Profile-30335.asp Introduction This analysis examines the historical and forecast performance for Boehringer Ingelheim in the ethical pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative [more] Pressrelease: While low-intensity therapies such as Vidaza, Dacogen and Revlimid have improved patient outcomes, higher-risk MDS remains a disease with poor prognosis www.companiesandmarkets.com adds new report - Stakeholder Opinions - Myelodysplastic Syndromes - First approvals spur some interest in a niche market http://www.companiesandmarkets.com/Summary-Market-Report/Stakeholder-Opinions-Myelodysplastic-Syndromes-First-approvals-spur-some-interest-in-a-niche-market-30334.asp Introduction Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic stem cell disorders. With a forecast incidence of 36,769 across the seven major markets in 2007, they are one of the most common hematological malignancies. Currently, the only potentially curative option [more] Pressrelease: Pharmaceutical industry ethical sales will increase at a modest 3.2% CAGR 2006 to 2012 www.companiesandmarkets.com adds new report - The Pharmaceutical Company Outlook to 2012 - Strategic Analysis of the Sales Outlook for Big Pharma, Mid Pharma, Japan Pharma and Biotech http://www.companiesandmarkets.com/Summary-Market-Report/The-Pharmaceutical-Company-Outlook-to-2012-Strategic-Analysis-of-the-Sales-Outlook-for-Big-Pharma,-Mid-Pharma,-Japan-Pharma-and-Biotech-30333.asp Introduction Based on an analysis of 43 companies and 1,200+ products, this report forecasts that pharmaceutical industry ethical sales will increase at a modest 3.2% CAGR 2006 to 2012. However, behind this industry average [more] Pressrelease: Advances in novel imaging techniques provide opportunities to diagnose and treat the most complex ACS cases www.companiesandmarkets.com adds new report - Stakeholder Insight - Acute Coronary Syndromes - Fresh look at ACS in Europe, what is the real picture http://www.companiesandmarkets.com/Summary-Market-Report/Stakeholder-Insight-Acute-Coronary-Syndromes-Fresh-look-at-ACS-in-Europe,-what-is-the-real-picture-30332.asp Introduction The face of ACS is changing. The ageing population and pressure of growing risk factors have made a significant impact on the management strategies in ACS. This report unveils the true picture through in-depth analysis of data [more] Pressrelease: The UI market is set to continue to grow over the next 6 years, reaching over $2.5 billion in 2012, a 68% increase from 2006 www.companiesandmarkets.com adds new report - Pipeline and Commercial Insight - Urinary Incontinence - Lifecycle management strategies retain mid-term market growth http://www.companiesandmarkets.com/Summary-Market-Report/Pipeline-and-Commercial-Insight-Urinary-Incontinence-Lifecycle-management-strategies-retain-mid-term-market-growth-30331.asp Introduction The UI market is set to continue to grow over the next 6 years, reaching over $2.5 billion in 2012, a 68% increase from 2006. Lifecycle management strategies, novel formulations and follow-on products will drive the majority of this growth, [more] Pressrelease: 10 players in infectious disease account for two thirds of 7 major market chemotherapeutic anti-infective sales by value www.companiesandmarkets.com adds new report - Commercial Insight - Infectious Diseases Overview http://www.companiesandmarkets.com/Summary-Market-Report/Commercial-Insight-Infectious-Diseases-Overview-30330.asp Introduction A total of 11 companies make up the top five across each of the four ID sectors, their core competencies ranging from a single disease area to generics prowess, producing a comprehensive portfolio to providing a specific offerings corresponding to highest unmet need. This report characterises the key players [more] Pressrelease: Healthcare system characteristics differ greatly between different emerging market countries www.companiesandmarkets.com adds new report - Emerging markets series - Benchmarking key countries Brazil, Russia, India, China and Turkey http://www.companiesandmarkets.com/Summary-Market-Report/Emerging-markets-series-Benchmarking-key-countries-Brazil,-Russia,-India,-China-and-Turkey-30329.asp Introduction With dwindling growth rates observed in the major developed markets many pharmaceutical companies are turning towards emerging market countries in order to sustain their revenue growth. While some countries, with double digit growth rates present tremendous opportunities, there are also many obstacles [more] Pressrelease: Increased access to the internet has led a growth in physician and patient websites www.companiesandmarkets.com adds new report - eHealthInsight Series - Reaching Doctors and Patients Through New Digital Media http://www.companiesandmarkets.com/Summary-Market-Report/eHealthInsight-Series-Reaching-Doctors-and-Patients-Through-New-Digital-Media-30328.asp Introduction Existing sales and marketing models are considered unsustainable. Pharma has been slow to adapt and take advantage of the marketing opportunities offered by the internet. Meanwhile customers are increasingly using the web to source information. Pharma needs to evolve and engage with their customers [more] Pressrelease: The global pharmaceuticals market grew by 5.5% in 2007 to reach a value of $577.2 billion. www.companiesandmarkets.com adds new report - Pharmaceuticals - Global Industry Guide http://www.companiesandmarkets.com/Summary-Market-Report/Pharmaceuticals-Global-Industry-Guide-30327.asp Pharmaceuticals: Global Industry Guide is an essential resource for top-level data and analysis covering the pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, [more] Pressrelease: The global OTC pharmaceuticals market grew by 4% in 2007 to reach a value of $84.8 billion. www.companiesandmarkets.com adds new report - OTC Pharmaceuticals - Global Industry Guide http://www.companiesandmarkets.com/Summary-Market-Report/OTC-Pharmaceuticals-Global-Industry-Guide-30326.asp The OTC Pharmaceuticals: Global Industry Guide is an essential resource for top-level data and analysis covering the OTC pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert [more] Pressrelease: The incidence of bone metastases across these tumor types in the seven major markets is forecasted to total 225,174 in 2008 www.companiesandmarkets.com adds new report - Stakeholder Opinions - Bone Metastases - Impending patent expiries may help make or break newer agents http://www.companiesandmarkets.com/Summary-Market-Report/Stakeholder-Opinions-Bone-Metastases-Impending-patent-expiries-may-help-make-or-break-newer-agents-30325.asp Introduction Bone metastases are a complication of some advanced cancers including cancers of the breast, lung, prostate, kidney and thyroid. The incidence of bone metastases across these tumor types in the seven major markets is forecasted to total 225,174 in [more] Pressrelease: The pharmaceutical industry is facing increasingly cost-conscious times, with a declining ROI and numerous blockbuster products facing imminent generic competition www.companiesandmarkets.com adds new report - The Pharmaceutical Industry 2008 - Current and Future Trends and Strategic Issues Shaping Pharma http://www.companiesandmarkets.com/Summary-Market-Report/The-Pharmaceutical-Industry-2008-Current-and-Future-Trends-and-Strategic-Issues-Shaping-Pharma-30324.asp Introduction Today, pharma companies face growing competition from generics and me-too drugs, combined with increasingly tough P&R, a clamp down on healthcare spending, and the need to treat patients for longer due to the aging population. These factors threaten both current and [more] Pressrelease: Manufacturers are looking to gain greater control over the drug supply chain www.companiesandmarkets.com adds new report - Pharmaceutical Supply chain strategies - Reassessing product distribution to cut costs and improve supply chain management http://www.companiesandmarkets.com/Summary-Market-Report/Pharmaceutical-Supply-chain-strategies-Reassessing-product-distribution-to-cut-costs-and-improve-supply-chain-management-30323.asp Introduction Ideally drug supply should be a simple and transparent chain that connects the manufacturer and patient in as few steps as possible, however in practice it can be a highly circuitous one that includes several intermediaries before reaching a [more] Pressrelease: Wyeth and Elan's bapineuzumab has potential to generate multi-billion dollar revenues, and become one of the most lucrative drugs in medicine. www.companiesandmarkets.com adds new report - Pipeline and Commercial Insight - Alzheimer's Disease - Scenario forecasts reveal vast market potential http://www.companiesandmarkets.com/Summary-Market-Report/Pipeline-and-Commercial-Insight-Alzheimers-Disease-Scenario-forecasts-reveal-vast-market-potential-30322.asp Introduction With the AD market entering a pivotal phase, this report contains several scenario forecasts in order to explore the possible market outlook over the next 10 years. Several pioneering Phase III disease slowing therapies offer blockbuster potential. However, should these drugs [more]